Kaplan–Meier analysis of cumulative rate of UST continuity for patients with UC post-UST administration. A, Cumulative rate of UST continuity in patients with UC post-UST administration. B, Comparison of the cumulative rate of UST continuity between UC patients with and without concomitant 5-ASA therapy. No significant differences were observed between the 2 groups (P = .0892). Abbreviation: 5-ASA, 5-aminosalicylic acid; UC, ulcerative colitis; UST, ustekinumab.